Current controversies about combined hormone therapy and the relative risks to the breast and endometrium

References

• Writing Group for Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2002;288:321–33
   Google Scholar
• The Women's Health Initiative Steering Com-mittee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women's Health Initiative randomized con-trolled trial. J Am MedAssoc2004;291:1701–12
   Google Scholar
• Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/ progestin Replacement Study follow-up (HERS II). J Am Med Assoc 2002;288: 49–57
   Google Scholar
• Hulley S, Furberg C, Barrett-Connor E, et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/ progestin Replacement Study follow-up (HERS II). J Am Med Assoc 2002;288: 58–66
   Google Scholar
• Million Women Study Collaborators. Breast cancer and hormone replacement therapy in the Million Women Study. Lancet 2003;362:419–27
   PubMed Web of Science ®Google Scholar
• Manson JE, Hsia J, Johnson KC, et al. for the Women's Health Initiative Investigators. Estro-gen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523–34
   Google Scholar
• Shapiro S. Risks of estrogen plus progestin therapy: a sensitivity analysis of findings in the Women's Health Initiative randomized con-trolled trial. Climacteric 2003;6:302–10
   PubMed Web of Science ®Google Scholar
• Hodis HN, Mack WJ, Azen SP, et al. for the Women's Estrogen-Progestin Lipid-Lowering Hormone Atherosclerosis Regression trial re-search Group. Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. N Engl J Med 2003;349:535–45
   Google Scholar
• Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 1997;350:1047–59
   PubMed Web of Science ®Google Scholar
• Bush TL, Whiteman M, Flaws JA. Hormone replacement therapy and breast cancer: a quali-tative review. Obstet Gynecol 2001;98:498–508
   Google Scholar
• Vestergaard P, Hermann AP, Stilgren L, et al. Effects of 5 years of hormonal replacement therapy on menopausal symptoms and blood pressure — a randomised controlled study. Maturitas 2003;46:123–32
   PubMed Web of Science ®Google Scholar
• Mosekilde L, Vestergaard P, Andresen J, et al. Effects of 10 years of estradiol on fracture risk and other outcomes in early postmenopausal women — the Danish Osteoporosis Prevention Study. Calcified Tissue Int 2004;74\(Suppl 1):538 (0P030)
   Google Scholar
• Chlebowski RT, Hendrix SL, Langer RD, et al. for the WHI Investigators. Influence of estrogen plus progestin on breast cancer and mammo-graphy in healthy postmenopausal women. The Women's Health Initiative Randomized Trial. J Am Med Assoc 2003;289:3243–53
   Google Scholar
• van der Mooren MJ, Kenemans P. The Million Women Study: a licence to kill other investiga-tions? Eur J Obstet Gynecol Reprod Biol 2004;113:3–5
   PubMed Web of Science ®Google Scholar
• Li CI, Malone KE, Porter PL, et al. Relation-ships between long durations and different regimens of hormone therapy and risk of breast cancer. J Am Med Assoc 2003;289:3254–63
   PubMed Web of Science ®Google Scholar
• Stahlberg C, Pedersen AT, Lynge E, et al. Increased risk of breast cancer following differ-ent regimens of hormone replacement therapy frequently used in Europe. Int J Cancer 2004;109:721–7
   PubMed Web of Science ®Google Scholar
• Tjonneland A, Christensen J, Thomsen BL. Hormone replacement therapy in relation to breast carcinoma incidence rate ratios. A pro-spective Danish cohort study. Cancer 2004;100:2328–37
   Google Scholar
• Pike MC, Peters RK, Cozen W, et al. Estrogen—progestin replacement therapy and endometrial cancer. J Natl Cancer Inst 1997;89:1110–6
   PubMed Web of Science ®Google Scholar
• Beresford SAA, Weiss NS, Voight LF, et al. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 1997;349:458–61
   PubMed Web of Science ®Google Scholar
• Weiderpass E, Adami HO, Baron JA, et al. Risk of endometrial cancer following estrogen repla-cement with and without progestins. J Natl Cancer Inst 1999;91:113–7
   Google Scholar
• Shapiro S, Kelly JP, Rosenberg L, et al. Risk of localized and widespread endometrial cancer in relation to recent and discontinued use of conjugated estrogens. N Engl J Med 1985;313: 969–72
   PubMed Web of Science ®Google Scholar
• Grady D, Gebretsadik T, Kerlikowske K, et al. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 1995;85:304–13
   PubMed Web of Science ®Google Scholar
• Weiderpass E, Baron JA, Adami HO, et al. Low-potency oestrogen and risk of endometrial cancer: a case-control study. Lancet 1999;353: 1824–8
   PubMed Web of Science ®Google Scholar
• Pukkala E, Tulenheimo-Silfvast A, Leminen A. Incidence of cancer among women using long versus monthly cycle hormonal replacement therapy, Finland 1994-1997. Cancer Causes Control 2001;12:111–5
   PubMed Web of Science ®Google Scholar
• Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of 'untreated' hyperplasia in 170 patients. Cancer 1985;56: 403–12
   Google Scholar
• Woodruff JD, Pickar JH. Incidence of endome-trial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated es-trogens alone. The Menopause Study Group. Am J Obstet Gynecol 1994;170:1213–23
   PubMed Web of Science ®Google Scholar
• Writing Group for the PEP Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Post-menopausal Estrogen/Progestin Interventions (PEP!) Trial. J Am Med Assoc 1996;275:370–5
   Google Scholar
• Sturdee DW, Ulrich LG, Barlow DH, et al. The endometrial response to sequential and continuous combined oestrogen—progestogen re-placement therapy. Br J Obstet Gynaecol 2000;107:1392–400
   Google Scholar
• Wells M, Sturdee DW, Barlow DH, et al. Effect on endometrium of long term treatment with continuous combined oestrogen—progestogen re-placement therapy: follow up study. Br Med J 2002;325:239–42
   PubMed Web of Science ®Google Scholar
• Pickar JH, Yeh IT, Wheeler JE, et al. Endome-trial effects of lower doses of conjugated equine estrogens and medroxuprogesterone acetate: two-year substudy results. Fertil Steril 2003;80:1234–40
   PubMed Web of Science ®Google Scholar
• Scarselli G, Tantini C, Colafranceshi M, et al. Levonorgestrel Nova T and precancerous lesions of the endometrium. Eur J Gynecol Oncol 1988;9:284–6
   PubMedGoogle Scholar
• Vilos GA, Harding PG, Ettler HC. Resectoscopic surgery in 10 women with abnormal uterine bleeding and atypical endometrial hyperplasia. J Am Assoc Gynecol Laparosc 2002;9: 138–44
   Google Scholar
• Gimpelson RJ. Not so benign endometrial hyperplasia: endometrial cancer after endome-trial ablation. J Am Assoc Gynecol Laporosc 1997;4:507–11
   PubMed Web of Science ®Google Scholar
• Cianferoni L, Giannini A, Franchini M. Hys-teroscopic resection of endometrial hyperplasia. J Am Assoc Gynecol Laparosc 1999;6:151–4
   PubMedGoogle Scholar
• Istre 0, Holm-Nielsen P, Bourne T, et al. Hormone replacement therapy after transcervi-cal resection of the endometrium. Obstet Gynecol 1996;88:767–70
   PubMedGoogle Scholar
• Koss LG, Schreiber K, Oberlander SG, et al. Detection of endometrial carcinoma and hyper-plasia in asymptomatic women. Obstet Gynecol 1984;64:1–11
   PubMed Web of Science ®Google Scholar
• Sturdee DW, Barlow DH, Ulrich LG, et al. Is the timing of withdrawal bleeding a guide to endometrial safety during sequential oestrogen—progestagen replacement therapy? Lancet 1994;344:979–82
   PubMed Web of Science ®Google Scholar
• Pickar JH, Archer DF. Is bleeding a predictor of endometrial hyperplasia in postmenopausal wo-men receiving hormone replacement therapy? Am J Obstet Gynecol 1997;177:1178–83
   PubMed Web of Science ®Google Scholar
• Archer DF, Lobo RA, Land HF, et al. A comparative study of transvaginal uterine ultra-sound and endometrial biopsy for evaluating the endometrium of postmenopausal women taking hormone replacement therapy. Menopause 1999;6:201–8
   PubMed Web of Science ®Google Scholar
• Trevoux R, De Brux J, Castanier M, Nahoul K, Soule JP, Scholler R. Endometrium and plasma hormone profile in the pen-menopause and postmenopause. Maturitas 1986;8:309–26
   PubMed Web of Science ®Google Scholar
• Poulsen HK, Jacobsen M, Bertelsen K, et al. Ugeskr Lceger 1997;159:3403–7
   PubMedGoogle Scholar
• Epstein E. Ultrasound in management of women with postmenopausal bleeding. Thesis. Faculty of Medicine. Lund University, 2001
   Google Scholar
• Vickers M, Meade T, Darbyshire J. WISDOM: history and early demise — was it inevitable? Climacteric 2002;5:317–25
   Google Scholar
• Fernandez E, Gallus S, Bosetti C, et al. Hormone replacement therapy and cancer risk: a systema-tic analysis from a network of case-control studies. Int J Cancer 2003;105:408–12
   PubMed Web of Science ®Google Scholar